Silence to Merge with Intradigm in Bid to Create Top RNAi Drug, Delivery Player | GenomeWeb

This story has been updated from a version posted on Dec. 16 to include additional comments from Intradigm's CEO.

By Doug Macron

Silence Therapeutics and Intradigm this week announced that they have agreed to merge in a bid to create an RNAi therapeutics firm with multiple drug-development and -delivery technologies, as well as a pipeline of both clinical and preclinical candidates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.